NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of NovoCure Limited (NASDAQ:NVCR - Get Free Report) have earned an average rating of "Moderate Buy" from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $32.83.

A number of analysts have recently commented on NVCR shares. Wedbush reduced their price target on shares of NovoCure from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 16th. Piper Sandler reiterated an "overweight" rating and issued a $34.00 price target on shares of NovoCure in a research note on Friday. JPMorgan Chase & Co. reduced their price target on shares of NovoCure from $29.00 to $28.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Finally, Wall Street Zen lowered shares of NovoCure from a "hold" rating to a "sell" rating in a research note on Friday, April 25th.

NovoCure Stock Up 5.3%

NASDAQ:NVCR opened at $18.00 on Friday. The firm has a market cap of $2.01 billion, a P/E ratio of -11.92 and a beta of 0.74. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.41 and a current ratio of 1.47. NovoCure has a fifty-two week low of $14.17 and a fifty-two week high of $34.13. The firm has a 50-day simple moving average of $17.66 and a two-hundred day simple moving average of $21.18.

NovoCure (NASDAQ:NVCR - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.16. NovoCure had a negative net margin of 26.41% and a negative return on equity of 45.46%. The business had revenue of $154.99 million during the quarter, compared to analyst estimates of $147.57 million. During the same period last year, the business earned ($0.36) EPS. NovoCure's revenue was up 11.9% compared to the same quarter last year. Analysts predict that NovoCure will post -1.3 earnings per share for the current fiscal year.

Institutional Trading of NovoCure

Large investors have recently added to or reduced their stakes in the business. GeoWealth Management LLC bought a new stake in NovoCure during the fourth quarter valued at approximately $27,000. Lindbrook Capital LLC grew its position in NovoCure by 189.2% during the fourth quarter. Lindbrook Capital LLC now owns 1,854 shares of the medical equipment provider's stock valued at $55,000 after buying an additional 1,213 shares during the period. GF Fund Management CO. LTD. bought a new stake in NovoCure during the fourth quarter valued at approximately $68,000. SBI Securities Co. Ltd. bought a new stake in NovoCure during the fourth quarter valued at approximately $70,000. Finally, Acadian Asset Management LLC bought a new stake in NovoCure during the first quarter valued at approximately $87,000. 84.61% of the stock is currently owned by institutional investors.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.